Background: Hepatitis C virus (HCV) is one of the most common transfusion transmissible infections hence the introduction of routine screening for its antibodies in blood donors in most blood banks.
INTRODUCTION
HCV is a single stranded RNA virus which until 1989 was named non A, non B hepatitis virus, was responsible for 80% of post transfusion hepatitis (1, 2, 3) . The modes of transmission are sexual intercourse, accidental inoculation (as in intravenous drug use, tattooing, acupuncture) with HCV-contaminated instruments, contact with infected body fluids and vertical transmission (4, 5, 6) . Sickle cell disease (SCD), haemophilia and haemodialysis are risk factors due to the need for repeated transfusion with blood and blood products (4, 5) . The seroprevalence of HCV antibodies ranges from 1.1% to 6.7% (7) in the West African sub-region.
Liver disease of variable course is the most common manifestation of HCV infection (4).
Pegylated α-interferon and/or Ribavirin are used for the treatment of HCV with variable outcomes (8) .
HCV antibody screening was introduced in ABUTH blood bank in 1997 and since then its prevalence has not been determined among blood donors which this paper seeks to do. 
Methods

